Use

The test is useful for the identification of neoplasms expressing programmed cell death 1-ligand 1 (PD-L1), a transmembrane protein that plays a role in immune response regulation. Overexpression of PD-L1 has been identified as a prognostic and theranostic marker across various neoplasms including carcinomas of the urinary bladder, lung, thymus, colon, pancreas, ovary, breast, kidney, as well as melanoma and glioblastoma. This biomarker is significant in predicting the response to PD-L1 inhibitors used in cancer therapies, particularly in patients with specific tumor types and treatment histories.